Galcanezumab is administered as a subcutaneous (under the skin) injection. It is available in prefilled syringes or autoinjector pens designed for patient self-administration after proper training by a healthcare professional.

• Administration Sites: You can inject galcanezumab into the abdomen, thigh, back of the upper arm, or buttocks.
• Preparation:
  • Store in the refrigerator (2°C to 8°C). Do not freeze.
  • Before injection, allow the pen/syringe to sit at room temperature for at least 30 minutes to warm up. Do not warm it using heat sources like hot water or a microwave.
  • Inspect the solution: It should be clear and colorless to slightly yellow. Do not use if it is cloudy, discolored, or contains visible particles.
  • Do not shake the pen/syringe.
• Injection Technique: Your healthcare provider will provide thorough training on how to use the specific device (autoinjector or prefilled syringe) you are prescribed, including proper aseptic (sterile) technique.
• Frequency and Dosage (Varies by Indication):
  • For Migraine Prevention:
    • Initial Loading Dose: 240 mg (given as two consecutive injections of 120 mg each) once. This higher initial dose helps the medication reach effective levels quickly.
    • Maintenance Dose: 120 mg (one injection) once every month.
  • For Episodic Cluster Headache Treatment:
    • Dose: 300 mg (given as three consecutive injections of 100 mg each) at the onset of a cluster period.
    • Frequency: Then, 300 mg once every month until the end of the cluster period.
• Missed Dose: If you miss a dose, administer it as soon as possible. Thereafter, resume your monthly dosing schedule from the date of the last dose.
• Single-Use Device: Each prefilled pen or syringe is for single use only. Dispose of it properly in a sharps container after one use, even if some medicine remains.
• Avoid Damaged Skin: Do not inject into skin that is tender, bruised, red, or hard.

Consistent monthly (or per cluster period) administration is crucial for the effectiveness of galcanezumab.

Galcanezumab works by targeting a specific molecule called Calcitonin Gene-Related Peptide (CGRP). CGRP is a naturally occurring protein that plays a crucial role in the development of migraine and cluster headache pain. During a migraine attack, levels of CGRP increase, contributing to inflammation and pain signaling in the brain.

Here’s how Galcanezumab intervenes:

• CGRP Ligand Binding: Galcanezumab is a monoclonal antibody designed to selectively bind to the CGRP ligand (the CGRP protein itself).
• Preventing Receptor Activation: By binding to CGRP, galcanezumab prevents CGRP from attaching to its receptor on nerve cells. This blocks the biological activity of CGRP.
• Interrupting Pain Signaling: By blocking CGRP’s ability to activate its receptor, galcanezumab effectively disrupts the pain signaling pathway believed to be involved in migraine and cluster headache. This reduces the frequency, severity, and duration of these headache types.

It’s important to note that galcanezumab does not block the CGRP receptor directly; instead, it “captures” the CGRP molecule itself, preventing it from ever reaching the receptor. This targeted mechanism helps to reduce the likelihood of headache attacks.

Like all medications, Galcanezumab can cause side effects, although not everyone experiences them. Most side effects are generally mild and localized.

Common side effects (affecting more than 1 in 10 people, often occurring at the injection site):

• Injection site reactions: Pain, redness (erythema), itching (pruritus), bruising, swelling, or lumps at the injection site. These are usually mild and temporary.

Less common side effects (affecting 1 in 10 to 1 in 100 people):

• Vertigo (a sensation of spinning or dizziness).
• Constipation.
• Rash.
• Itching (generalized, not just at injection site).

Serious, but rare, side effects that require immediate medical attention:

• Serious Allergic Reactions (Hypersensitivity): This is the most significant serious warning. Symptoms can include:
  • Rash, hives, itching (severe).
  • Swelling of the face, mouth, tongue, or throat (angioedema).
  • Difficulty breathing or swallowing.
  • Low blood pressure (can cause dizziness or lightheadedness).
  • These reactions can occur minutes to days (or even up to 4 weeks) after injection and can be prolonged. Seek emergency medical help right away if you experience any of these symptoms.
• Hypertension (High Blood Pressure): New onset hypertension or worsening of pre-existing hypertension has been reported in the post-marketing setting. This can occur at any time but is most frequently reported within 7 days of initiation.
• Raynaud’s Phenomenon: Development or worsening of Raynaud’s phenomenon (reduced blood flow to fingers/toes causing numbness, tingling, or coldness) has been reported.

Always report any new, unusual, or severe symptoms to your doctor immediately.

Before prescribing Galcanezumab, your doctor will carefully evaluate your medical history due to several important warnings and precautions:

• Hypersensitivity Reactions: Galcanezumab is contraindicated (should not be used) in patients who have a serious hypersensitivity (allergic reaction) to galcanezumab or any of its ingredients. As mentioned, serious allergic reactions, including anaphylaxis and angioedema, can occur and may be delayed or prolonged. Patients should be educated on these risks and instructed to seek immediate medical help if symptoms occur.
• Cardiovascular Disease: Patients with certain major cardiovascular diseases were excluded from clinical studies. Therefore, there is limited safety data available for these patients. Your doctor will weigh the benefits against potential risks if you have significant cardiovascular conditions. New-onset or worsening hypertension has been reported in the post-marketing setting.
• Immunogenicity: As with other therapeutic proteins, there is a potential for immunogenicity (the development of antibodies against the drug). The development of anti-drug antibodies could theoretically impact the drug’s effectiveness or lead to allergic reactions, though clinical significance often varies.
• Pregnancy: There is limited data on galcanezumab use in pregnant women. Animal studies suggest potential risks. Galcanezumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, discuss this with your doctor. A pregnancy registry exists to monitor outcomes.

Galcanezumab generally has a very low potential for drug-drug interactions. This is because, as a monoclonal antibody, it is a large protein that is broken down by different pathways in the body (proteolytic degradation) than most small-molecule drugs (which often involve liver enzymes like the cytochrome P450 system).

• No Known Significant Interactions: Clinical studies and post-marketing experience have not identified any significant drug-drug interactions with galcanezumab. It is not expected to interact with common medications for other conditions or with other migraine treatments.
• Other CGRP Inhibitors: You should generally not use galcanezumab concurrently with other CGRP inhibitors (e.g., erenumab, fremanezumab, eptinezumab) or other CGRP-targeting medications (like oral gepants such as rimegepant or ubrogepant) unless specifically directed by your doctor, as this could increase the risk of side effects without added benefit.
• Alcohol/Cannabis/Herbal Products: There are no specific reported interactions with alcohol, cannabis, or herbal products. However, alcohol can be a migraine trigger for some individuals, and caution is always advised.

The dosage of Galcanezumab is specific to the condition being treated and follows a precise injection schedule.

• For Migraine Prevention (Adults):
  • Loading Dose: 240 mg (given as two consecutive subcutaneous injections of 120 mg each) once. This is the first dose.
  • Maintenance Dose: 120 mg (one subcutaneous injection) once monthly.
• For Episodic Cluster Headache Treatment (Adults):
  • Dose: 300 mg (given as three consecutive subcutaneous injections of 100 mg each).
  • Frequency: Administer at the onset of a cluster period, and then monthly until the end of the cluster period.
• Administration: Subcutaneous injection into the abdomen, thigh, back of the upper arm, or buttocks.
• Missed Dose: If a dose is missed, it should be administered as soon as possible. Thereafter, the regular monthly dosing can be resumed from the date of the last administration.
• No Dose Adjustments: No dose adjustments are required for elderly patients or those with mild to moderate renal or hepatic impairment. It has not been studied in severe impairment.

Treatment should be initiated by a physician experienced in the diagnosis and treatment of migraine or cluster headache. The benefit of treatment should be assessed within 3 months of initiation, and regular evaluation of the need for continued treatment is recommended.

Galcanezumab (Emgality) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system globally. Its strict prescription requirements are due to several crucial factors:

• Targeted Biologic Therapy: As a monoclonal antibody, it is a complex biological medicine that targets specific pain pathways, requiring a precise diagnosis.
• Specialist Oversight: Treatment should be initiated and supervised by physicians experienced in the diagnosis and treatment of migraine or cluster headache, such as neurologists.
• Diagnosis Confirmation: The conditions it treats (migraine and cluster headache) require a thorough medical evaluation to confirm the diagnosis and rule out other underlying causes of headache.
• Administration Method: It is an injectable medication, and while self-administered, requires initial training by a healthcare professional to ensure proper and safe technique.
• Potential for Serious Side Effects: Although generally well-tolerated, the risk of serious allergic reactions and other adverse events necessitates medical supervision.
• High Cost: As a specialized biologic, it typically comes with a high cost, and its use is often subject to specific criteria set by health authorities or insurance providers.

Therefore, a licensed medical doctor, often a neurologist or a pain specialist, must prescribe Galcanezumab.

What is Galcanezumab used for? Prevention of migraine and treatment of episodic cluster headache

2. What is the active ingredient? Galcanezumab‑gnlm

3. What drug class does it belong to? Monoclonal antibody (CGRP antagonist)

4. Is Galcanezumab a controlled substance? No

5. Is Galcanezumab available in generic form? No

6. How is Galcanezumab administered? Subcutaneous injection

7. What strengths are available? 120 mg/mL prefilled syringe or autoinjector

8. What is the usual adult dosage? 240 mg loading dose (two injections), then 120 mg monthly

9. Can it be used in children? Not approved for pediatric patients

10. What are common side effects? Injection site reactions, constipation, dizziness

11. Can it cause serious reactions? Rare—hypersensitivity reactions, severe allergic responses

12. Is Galcanezumab safe during pregnancy? Limited data; use only if benefits outweigh risks

13. Is a prescription required? Yes

14. Is Galcanezumab available in Pakistan? Not widely; may be accessed via specialty import

15. How should it be stored? Refrigerated at 2–8°C; protect from light; do not freeze

16. How long does it take to work? Some patients see benefit within the first month; full effect may take 2–3 months

17. Is Galcanezumab a cure for migraine? No—it reduces frequency/severity but does not cure migraine

18. What precautions should be taken during use? Monitor for allergic reactions; avoid use if hypersensitive to monoclonal antibodies

19. What are contraindications? Known hypersensitivity to galcanezumab or excipients

20. What are similar drugs? Erenumab (Aimovig), Fremanezumab (Ajovy), Eptinezumab (Vyepti)